UCB's Head of Corporate Strategy On Deals, Divestments And Sector-Wide Challenges
UCB's recently appointed head of corporate strategy and business development Alexander Moscho, who joined the company in October 2017, talks to Scrip about UCB's future growth, internal R&D pipeline and potential for significant deal-making in 2018.
You may also be interested in...
Early clinical-stage products for neurological and autoimmune diseases are progressing through the European biopharma's pipeline.
Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
Following the growing trend of pharmaceutical companies embracing patient-centric business models, Sanofi has appointed Dr Anne C Beal chief of patient affairs. The French pharma is the first of the top ten biopharmaceutical companies to create space for such a position, according to Pascale Witz executive vice-president of global and strategic development.